Eli Lilly has a lot of innovation that goes beyond obesity drugs: analyst

Eli Lilly CEO talks expanding innovation past obesity drugsПодробнее

Eli Lilly to Boost Obesity Drug Supply With Germany FactoryПодробнее

Eli Lilly goes direct-to-consumer on weight loss drugs: What patients and investors need to knowПодробнее

New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesПодробнее

Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan SeigermanПодробнее

Eli Lilly CEO on Fighting Obesity, Developing New DrugsПодробнее

Potential for Weight-Loss Drugs Boosts Eli LillyПодробнее

BofA's Geoff Meacham on Eli Lilly on Q4 results: The story has changed to diabetes and obesityПодробнее

FDA Approves Eli Lilly’s Zepbound Drug for Weight LossПодробнее

Eli Lilly goes direct-to-consumer on weight loss drugs #ShortsПодробнее

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more productПодробнее

Exclusive: How Eli Lilly’s making weight loss drugs more accessibleПодробнее

Eli Lilly seeking fast-track FDA approval for obesity drug tirzepatideПодробнее

Eli Lilly launches online direct-to-consumer pharmacy to help patients get weight loss drugsПодробнее

Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet itПодробнее

Eli Lilly releases new data from potentially game-changing weight loss drug trialПодробнее

Celebrities slammed for using diabetes, weight loss drugs by Eli LillyПодробнее

FDA approves new obesity drug Zepbound from Eli LillyПодробнее